Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocuphire Pharma Inc OCUP

Healthcare
Ocuphire Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. The Company’s lead retinal product candidate, APX3330, is a small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref1 is a regulator of transcription factors such as HIF-1a... see more

Recent & Breaking News (NDAQ:OCUP)

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update

GlobeNewswire March 30, 2023

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting

GlobeNewswire March 23, 2023

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings

GlobeNewswire February 16, 2023

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis

GlobeNewswire February 13, 2023

Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

GlobeNewswire January 25, 2023

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

GlobeNewswire January 9, 2023

Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis

GlobeNewswire December 6, 2022

Ocuphire to Present at Five Upcoming Investor/Industry Conferences

GlobeNewswire November 21, 2022

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

GlobeNewswire November 7, 2022

Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update

GlobeNewswire November 4, 2022

Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)

GlobeNewswire November 2, 2022

Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting

GlobeNewswire October 24, 2022

Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

GlobeNewswire October 7, 2022

Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease

GlobeNewswire October 6, 2022

Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team

GlobeNewswire September 29, 2022

Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

GlobeNewswire September 15, 2022

Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA

GlobeNewswire September 12, 2022

Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

GlobeNewswire September 8, 2022

Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update

GlobeNewswire August 12, 2022